Retinoblastoma is hereditary in about 30 to 40 percent of cases. The remaining 60 to 70 percent are caused by random genetic mutations that occur only in the eye and are not passed down through families. Understanding which type a child has changes everything about monitoring, family planning, and long-term health risks.
How the Two Types Differ
In hereditary retinoblastoma, a child is born with a mutation in one copy of the RB1 gene in every cell of their body. This mutation can be inherited from a parent or can arise spontaneously in the egg or sperm before conception. Because the mutation is already present bodywide, it only takes one additional mutation in a retinal cell to trigger tumor growth. That’s why the hereditary form tends to appear earlier, with a mean age at diagnosis of about 12 months, and often affects both eyes. Around 80 percent of hereditary cases are bilateral, and 67 percent involve multiple tumors.
Non-hereditary retinoblastoma requires two independent mutations to occur by chance in the same retinal cell. Because this is statistically unlikely, it almost always produces a single tumor in one eye and tends to show up later, with a mean diagnosis age around 24 months. These cases carry no increased risk for the child’s future siblings or offspring.
The Two-Hit Mechanism
The RB1 gene acts as a brake on cell division. The protein it produces stops cells from multiplying uncontrollably by binding to a key growth signal and switching it off. It also helps maintain the structural integrity of DNA packaging inside the cell. Both copies of RB1 must be knocked out before a retinal cell loses this brake entirely and begins forming a tumor.
In the hereditary form, the first “hit” is the germline mutation a child is born with. The second hit is a random somatic mutation that disables the remaining working copy of RB1 in a retinal cell. In the non-hereditary form, both hits must happen independently in the same cell, which is why it’s rarer and almost always produces just one tumor.
Inheritance Pattern and Penetrance
Hereditary retinoblastoma follows an autosomal dominant pattern. That means only one copy of the mutated gene is needed for the condition to be heritable, and it does not skip one sex over another. A parent carrying a germline RB1 mutation has a 50 percent chance of passing it to each biological child.
Penetrance, the likelihood that someone carrying the mutation actually develops a tumor, is remarkably high. Complete loss-of-function mutations in RB1 show greater than 99 percent penetrance. Fewer than 10 percent of families carry what’s called a “low-penetrance” variant, where the mutation still functions partially. In those families, penetrance drops to 25 percent or lower, and affected children are more likely to develop tumors in only one eye.
Mosaicism Complicates the Picture
Not every case fits neatly into “hereditary” or “non-hereditary.” Some children are mosaic, meaning the RB1 mutation occurred very early in embryonic development and is present in only a fraction of their cells. In documented cases, as few as 2 to 4 percent of blood cells carried the mutation. These children typically present with unilateral disease and can be misclassified as non-hereditary on standard testing.
Mosaicism matters for family planning. Even when standard blood tests don’t detect a germline mutation, there’s an estimated 1.2 percent chance the parent carries the mutation in a small subset of cells, including reproductive cells. That translates to roughly a 0.6 percent risk of passing the mutation to an offspring. It’s a small number, but not zero, which is why genetic counseling is recommended even after a seemingly non-hereditary diagnosis.
How Genetic Testing Works
Genetic testing for RB1 mutations can be performed on blood, saliva, or cheek swabs. Testing is most strongly recommended for children with bilateral tumors, multiple tumors in one eye, or a family history of retinoblastoma. If a germline mutation is confirmed, siblings are typically offered testing and ongoing eye screening as well.
When tumor tissue is available, doctors can also compare the mutations found in the tumor to those in the blood. If the blood test comes back negative but the tumor shows RB1 mutations, mosaicism remains a possibility, and the family may be counseled accordingly.
Risk of Other Cancers Later in Life
Children with the hereditary form face health considerations well beyond the eyes. Because the RB1 mutation exists in every cell, it raises the lifetime risk of developing other cancers. The most significant risks are soft tissue sarcomas, bone sarcomas, and melanoma. A large study tracking hereditary retinoblastoma survivors found that 33 percent developed at least one additional malignancy within 50 years of their original diagnosis, and 6 percent developed two or more.
Survivors also face elevated risks for certain epithelial cancers of the central nervous system, nasal cavity, oral cavity, and breast. Notably, the study did not find increased risks for kidney, bladder, uterine, pancreatic, or lung cancers compared to the general population. This risk profile means hereditary retinoblastoma survivors benefit from long-term cancer surveillance throughout adulthood.
Family Planning Options
Parents who carry a germline RB1 mutation or who have had hereditary retinoblastoma themselves have reproductive options beyond leaving things to chance. Preimplantation genetic testing during IVF allows embryos to be screened for the RB1 mutation before transfer. Only unaffected embryos are implanted, which effectively eliminates the 50 percent transmission risk for that pregnancy.
A cost-effectiveness study modeling 100 couples found that this approach, even at a 50 percent uptake rate, resulted in a net cost savings of nearly 2.75 million Australian dollars over 18 years compared to natural conception, largely because of the reduced need for cancer treatment in affected children. The approach also produced a small but measurable improvement in quality of life per child born. The trade-off is that IVF with genetic testing produces fewer total pregnancies and live births than natural conception, and access varies by country. In the UK, for example, it’s funded through the public health system, while in Australia the genetic testing component is an out-of-pocket expense.
For families already expecting, prenatal testing through amniocentesis or chorionic villus sampling can identify the mutation during pregnancy, allowing parents to prepare for early screening and intervention if needed.